Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
211At-AstraTate
- Development stage
- Preclinical
- Lead developer
- TetraKit Technologies
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
211At-AstraTate (also known as AstraTate or OCT-TBD) is a preclinical-stage targeted alpha-particle therapy (TAT) being developed by TetraKit Technologies, a spin-off from the University of Copenhagen, for the treatment of neuroendocrine tumors (NETs). The radiopharmaceutical consists of the somatostatin receptor type 2 (SSTR2)-targeting peptide octreotate labeled with the alpha-emitting radionuclide astatine-211 (211At) using TetraKit's proprietary tetrazine-based radiolabeling platform. By targeting SSTR2, which is highly overexpressed on neuroendocrine tumor cells, the drug delivers highly localized, high-energy alpha radiation directly to the tumor site, causing lethal double-strand DNA breaks while minimizing damage to surrounding healthy tissues.
- Other names
- AstraTate
02
Targets
SSTR2 (Somatostatin receptor type 2)DNA
Beyond the preview
Go deeper on 211At-AstraTate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 211At-AstraTate.